You are in: eMedicine Specialties > Emergency Medicine > WARFARE - CHEMICAL, BIOLOGICAL, RADIOLOGICAL, NUCLEAR AND EXPLOSIVES CBRNE - Incendiary Agents, Magnesium and ThermiteArticle Last Updated: May 16, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Jonathan L Burstein, MD, Assistant Professor of Population and International Health, Harvard School of Public Health; Director and Chair, Section of Disaster Medicine, Division of Emergency Medicine, Harvard Medical School Jonathan L Burstein is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Massachusetts Medical Society, National Association of EMS Physicians, and Society for Academic Emergency Medicine Editors: Mark Keim, MD, Director, Emergency and Disaster Public Health Sciences, Adjunct Assistant Professor, Department of Emergency Medicine, Emory University, National Center for Environmental Health, Centers for Disease Control and Prevention; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Robert G Darling, MD, FACEP, Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Director, Center for Disaster and Humanitarian Assistance Medicine Author and Editor Disclosure Synonyms and related keywords: incendiaries, metal incendiaries, Mg, thermate, thermal burn, incendiary agents, magnesium, thermite, thermal injuries, chemical warfare, magnesium burns, thermite burns, magnesium injury, thermite injury INTRODUCTIONBackgroundTwo major types of metal incendiaries exist, those that are magnesium based and those of the thermite/thermate type. Most types generally are encountered only in the military or industrial setting. Magnesium, a silvery white metal of atomic weight 24.32, ignites at 632°C and burns at 1982°C, with magnesium oxide (MgO) as its combustion product. In an exothermic reaction, metallic magnesium can ignite to produce magnesium dihydroxide (ie, Mg(OH)2) and hydrogen. Magnesium is used in either powdered or solid form as an incendiary agent for both illumination and antipersonnel purposes. Various alloys of magnesium (eg, aluminum/zinc/magnesium alloy found in US M126 round) are mechanically sturdier but also can be ignited easily. Thermite is a mixture of powdered or granular aluminum and powdered iron oxide. When combined with other substances, such as binders, the material is termed a "thermate." All such materials react vigorously when heated to the combustion temperature of aluminum. This reaction produces aluminum oxide, elemental iron, and sufficient heat to melt the iron. The reaction temperature is approximately 2200°C. Because the burning temperature of these chemicals is so high, standard hazardous-materials clothing (even Level A self-contained and chemical-proof clothing) is not protective. PathophysiologyBurning thermite or magnesium produces predominantly thermal injury, but residual particles (especially of magnesium) may produce chemical injury to the eyes, skin, and respiratory tract. Most injuries are thermal burns, which may be considered identical to deep partial or full-thickness thermal burns (see Burns, Thermal). Mortality/MorbidityOutcome of thermite or ignited magnesium burns is essentially the same as for identical thermal burns. CLINICALHistoryThe history usually makes the nature of the exposure evident, as the patient or rescuer describes the circumstances leading to exposure to thermite or magnesium incendiaries. In the event that a patient presents with burn injury and is unable to give a history, consider exposure to magnesium, thermite, or other hazardous materials. Obtain the patient's relevant medical history. In decision making, consider diseases that may affect healing (eg, diabetes mellitus, vascular disease) as well as drug allergies. PhysicalIncendiary agents produce predominantly dermatologic and respiratory effects.
CausesExposure to thermite or burning magnesium likely would occur in the context of military or paramilitary actions (including terrorist activities) or as a result of an industrial or scientific laboratory accident. Exposure potentially could occur as a result of a transportation accident. DIFFERENTIALSAcute Respiratory Distress Syndrome Burns, Chemical Burns, Ocular Burns, Thermal CBRNE - Chemical Warfare Agents Corneal Abrasion Gas Gangrene Hazmat
|
| Drug Name | Oxygen |
|---|---|
| Description | Used to support respiration and metabolism. |
| Adult Dose | 100% oxygen inhaled; reduce to 60% or less as soon as tolerated to minimize oxygen toxicity |
| Pediatric Dose | Administer as in adults |
| Contraindications | COPD, oxygen toxicity |
| Interactions | None reported |
| Pregnancy | A - Safe in pregnancy |
| Precautions | Inspired oxygen concentrations from 50-100% carry a substantial risk of lung damage |
Used to maintain hydration and salt balance.
| Drug Name | Lactated Ringer with normal saline |
|---|---|
| Description | Usually crystalloids such as normal saline or Ringer lactate; little indication for colloid use in acute burn management. |
| Adult Dose | For resuscitation, 2-4 cm3/kg per percent of TBSA burned to partial thickness or deeper; administer one half of this amount over 8 h and one half over next 16 h; adjust based on central venous pressure, systolic blood pressure, and urine output |
| Pediatric Dose | Administer as in adults |
| Contraindications | Major complication of isotonic fluid resuscitation is interstitial edema; edema of extremities is unsightly but not a significant complication; edema in brain or lungs is potentially fatal; major contraindication to isotonic fluid resuscitation is pulmonary edema; added fluid promotes more edema and may lead to development of ARDS |
| Interactions | None reported |
| Pregnancy | A - Safe in pregnancy |
| Precautions | Isotonic fluids administered during resuscitation of septic shock require close monitoring of cardiovascular and pulmonary function; stop fluids when desired hemodynamic response is seen or pulmonary edema develops |
Topical burn-healing and antimicrobial properties.
| Drug Name | Silver sulfadiazine (Silvadene) |
|---|---|
| Description | Contains both a sulfa antibiotic and a silver ion, which is an antibacterial; speeds burn healing and eases debridement. |
| Adult Dose | Topical application to burned area q12h |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity, G-6-PD deficiency |
| Interactions | Effect of proteolytic enzymes is reduced when used concomitantly with this product |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in G-6-PD deficiency and renal insufficiency; may cause "tattooing" on the face and should not be used on facial burns in most situations |
Antibacterial and to aid in burn healing.
| Drug Name | Bacitracin (AK-Tracin, Baciguent) |
|---|---|
| Description | Mild topical antibiotic, usually in an ointment base, for use on facial burns not deep enough to require grafting. |
| Adult Dose | Apply topically qid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; vaccinia, varicella, epithelial herpes simplex keratitis, mycobacterial infections, and fungal diseases of the eye; patients using steroid combinations after uncomplicated removal of a corneal foreign body |
| Interactions | None reported |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Ophthalmic ointments may delay healing of corneal epithelia; in deep-seated eye infections, supplement with systemic medications; prolonged use may result in overgrowth of nonsusceptible organisms |
Used to immunize patients against tetanus.
| Drug Name | Tetanus toxoid |
|---|---|
| Description | Used to induce active immunity. Immunizing agents of choice for most adults and children > 7 y are tetanus and diphtheria toxoids. Necessary to administer booster doses to maintain tetanus immunity throughout life. Pregnant patients should receive only tetanus toxoid, not a diphtheria antigen-containing product. In children and adults, may administer into deltoid or midlateral thigh muscles. In infants, preferred site of administration is the mid thigh laterally. |
| Adult Dose | Primary immunization: 0.5 mL IM; give 2 injections 4-8 wk apart and a third dose 6-12 mo after second injection Booster dose: 0.5 mL q10y |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; a history of any type of neurologic symptoms or signs following administration of this product; FDA recommends that elective tetanus immunization be deferred during any outbreak of poliomyelitis because tetanus toxoid injections are an important cause of provocative poliomyelitis |
| Interactions | Patients receiving immunosuppressants, including corticosteroids or radiation therapy, may remain susceptible despite immunization due to poor immune response; cimetidine may enhance or augment delayed-hypersensitivity responses to skin-test antigens; avoid concurrent use of medication with systemic chloramphenicol since it may impair amnestic response to tetanus toxoid; concurrent use of tetanus immune globulin may delay development of active immunity by several days (interaction is nevertheless clinically insignificant and does not preclude concurrent use) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use to treat actual tetanus infections or for immediate prophylaxis of unimmunized individuals (use instead tetanus antitoxin, preferably human tetanus immune globulin); diminished antibody response to active immunization may be seen in patients receiving immunosuppressive therapy; better to defer primary diphtheria immunization until immunosuppressive therapy discontinued; routine immunization of symptomatic and asymptomatic HIV-infected persons is recommended |
| Drug Name | Tetanus immune globulin (Hyper-Tet) |
|---|---|
| Description | Used for passive immunization of any person with a wound that may be contaminated with tetanus spores. |
| Adult Dose | Prophylaxis: 250-500 U IM in opposite extremity to tetanus toxoid lesion Clinical tetanus: 3000-10,000 U IM |
| Pediatric Dose | Prophylaxis: 250 U IM in opposite extremity to tetanus toxoid Clinical tetanus: 3000-10,000 U IM |
| Contraindications | Since antibodies in globulin preparation may interfere with immune response to vaccination, do not administer within 3 mo of live virus immune globulin administration; may be necessary to revaccinate persons who received immune globulin shortly after live virus vaccination |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Persons with isolated IgA deficiency have potential for developing antibodies to IgA and may have anaphylactic reactions to subsequent administration of blood products that contain IgA; do not perform skin testing since intradermal injection of concentrated gamma globulin may cause localized area of inflammation and can be misinterpreted, causing medication to be withheld from a patient not allergic to this material; true allergic responses to human gamma globulin given in prescribed IM manner are extremely rare; do not admix with other medications since usually incompatible |
CBRNE - Incendiary Agents, Magnesium and Thermite excerpt
Article Last Updated: May 16, 2006